Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.,Lung Cancer

当前位置： X-MOL 学术 › Lung Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Lung Cancer ( IF 4.5 ) Pub Date : 2019-12-05 , DOI: 10.1016/j.lungcan.2019.12.003
Joan Gibert ₁ , Sergi Clavé ₂ , Max Hardy-Werbin ₁ , Álvaro Taus ₃ , Pedro Rocha ₃ , Raquel Longarón ₂ , Gabriel Piquer ₂ , Imane Chaib ₄ , Enric Carcereny ₄ , Teresa Morán ₄ , Marta Salido ₂ , Alba Dalmases ₂ , Beatriz Bellosillo ₂ , Edurne Arriola ₅

Affiliation

OBJECTIVES KRAS mutations are one of the most prevalent alterations in non-small cell lung cancer. However, patients with this driver alteration present heterogeneous clinical outcomes. In this study, we have explored the potential clinical impact of coexisting alterations in this subset of patients. MATERIALS AND METHODS Samples from a cohort of 69 lung adenocarcinoma patients homogenously treated with platinum doublet as first-line therapy were evaluated using targeted next generation sequencing (NGS). Mutations and copy number alterations were assessed in 37 advanced KRAS-mutant (KRASm) and in 32 KRAS wild-type (KRASwt). RESULTS TP53 was the most frequent additional alteration found in both cohorts. Interestingly, TP53 mutations were more frequent in KRASwt than in KRASm patients (80 % vs. 34 %; p <  0.05) as well as STK11 mutations (17 % vs 8 %, p=NS). FGFR3 mutations were only found concomitantly with KRASm (11 %). No genomic co-alteration had an impact on overall survival within the KRASm patients treated with chemotherapy. CONCLUSIONS KRAS mutated lung adenocarcinoma is a heterogeneous entity and comprehensive characterization of co-alterations using NGS may lead to more accurate patient stratification.

更新日期：2019-12-05

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11